Report on recent treatment of Hodgkin's lymphoma in the 53rd annual meeting of American Society of Hematology

VernacularTitle:霍奇金淋巴瘤最新治疗进展:第53届美国血液学会年会深度报道
Author: Zhijian ZOU ; Wei XU ; Jianyong LI
Publication Type:Journal Article
Keywords: Hodgkin's lymphoma; Transplant; American Society of Hematology annual meeting
From: Journal of Leukemia & Lymphoma 2012;21(2):70-72
CountryChina
Language:Chinese
Abstract: Hodgkin's lymphoma(HL)is a highly curable malignancy for most patients during the recent decades.Frontline treatment is generally ABVD alone or in combination with other chemotherapy regimens or radiation. To achieve a higher control of disease, ABVD chemotherapy has been challenged by more intensive treatments, such as Stanford V and BEACOPP regimen. In the 53rd ASH annual meeting,ABVD is still widely accepted as standard regimen for HL, even in elderly people or patients with HIV infection. Relapsed or refractory HL is a challenging problem for clinician, and high dose chemotherapy followed by autologous stem cell transplantation(HDC/ASCT)is the preferred treatment for chemoresistant patients.Many novel treatment strategies were explored for these patients.Positron emission tomography (PET) scanning provides important prognostic information in patients with HL receiving chemotherapy or pre/posttransplant,but the utility of long term surveillance radiological studies is not recommended in the meeting.